Adverse events related to biologicals used for patients with multiple sclerosis: a comparison between information originating from regulators and information originating from the scientific community

BACKGROUND AND PURPOSE: Clinical decision making is facilitated by healthcare professionals’ and patients’ adequate knowledge of the adverse events. This is especially important for biologicals used for treating multiple sclerosis (MS). So far, little is known about whether different information sou...

Descripción completa

Detalles Bibliográficos
Autores principales: Minnema, L. A., Giezen, T. J., Egberts, T. C. G., Leufkens, H. G. M., Gardarsdottir, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384026/
https://www.ncbi.nlm.nih.gov/pubmed/32298524
http://dx.doi.org/10.1111/ene.14259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384026/
https://www.ncbi.nlm.nih.gov/pubmed/32298524
http://dx.doi.org/10.1111/ene.14259

Ejemplares similares